Samsung Bioepis Joins Biosimilar Lucentis Fray As It Unveils Phase III Plans
Executive Summary
Samsung Bioepis has said it is preparing a Phase III trial with a proposed ranibizumab biosimilar, joining a number of players developing biosimilar versions of the ophthalmic use drug, which loses its first major patents in the next few years.